Detail akcie Anavex Life Science online

Business Summary: Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.
Financial Summary: BRIEF: For the nine months ended 30 June 2026, Anavex Life Sciences Corp revenues was not reported. Net loss decreased 91% to $3.2M. Lower net loss reflects Biopharmaceutical segment loss decrease of 52% to $6.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.42952 to -$0.03701.